{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:23:23Z","timestamp":1788927803890,"version":"build-2803163510"},"reference-count":39,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["clinical-practice-and-epidemiology-in-mental-health.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["CPEMH"],"published-print":{"date-parts":[[2021,2,16]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Extrapyramidal Symptoms (EPS) are unwanted symptoms commonly originating from the use of certain medications. The symptoms can range from minimal discomfort to permanent involuntary muscular movements. The aims of the study were to examine the incidence of drug-induced extrapyramidal symptoms (di-EPS), associated risk factors, and clinical characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This is a retrospective, observational study of di-EPS conducted in outpatient clinics of Jordan using the longitudinal health database (Hakeem\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) for data collection. Patients who received drugs with the risk of EPS during the period 2010-2020 were included and followed. Patients with any of the known underlying conditions that may cause EPS or were currently taking drugs that may mask the symptoms were excluded. Gender and age-matched control subjects were included in the study. The Statistical Package for Social Science (SPSS\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) version 26 was used for data analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The final dataset included 34898 exposed patients and 69796 matched controls. The incidence of di-EPS ranged from 9.8% [Amitriptyline 25mg] to 28.9% (Imipramine 25mg). Baseline factors associated with a significantly higher risk of developing di-EPS were age {HR: 1.1 [95%CI: 0.8-1.2, p=0.003], smoking {HR: 1.7 (95%CI: 1.3-2.2), p=0.02}, tremor history {HR: 7.4 (95%CI: 5.9-8.3), p=.002} and history of taking antipsychotics {HR: 3.9, (95% CI: 2.5-4.6), p=0.001}. Patients taking paroxetine {HR: 8.6 [95%CI: 7.4-9.8], p=.0002},imipramine {HR: 8.3, [7.1-10.5], p=0.01}, or fluoxetine {HR: 8.2 (95%CI: 6.8-9.3), p=.006} had a significantly higher risk of developing di-EPS compared to patients taking citalopram. Myoclonus, blepharospasm, symptoms of the basal ganglia dysfunction, and organic writers' cramp were reported among participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Patients treated with paroxetine, imipramine, fluoxetine, or clomipramine had a higher risk of developing di-EPS than patients treated with citalopram. The difference in gender was not significantly related to di-EPS development. Whereas age, smoking, and history of taking antipsychotics were significantly associated with di-EPS development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings:<\/jats:title>\n                    <jats:p>\u2022 High incidence of drug-induced extrapyramidal symptoms (di-EPS) was reported<\/jats:p>\n                    <jats:p>\u2022 Age, smoking, tremor history, and history of taking antipsychotics were risk factors of drug-induced extrapyramidal symptoms.<\/jats:p>\n                    <jats:p>\u2022 Patients taking paroxetine, imipramine or fluoxetine had a significantly higher risk of developing di-EPS compared to patients taking citalopram<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1745017902117010001","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T01:55:14Z","timestamp":1613440514000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Assessment of Extrapyramidal Symptoms Associated with Psychotropics Pharmacological Treatments, and Associated Risk Factors"],"prefix":"10.2174","volume":"17","author":[{"given":"Dania","family":"Abu-Naser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gharaibeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Z.","family":"Al Meslamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qais","family":"Alefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renad","family":"Abunaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","volume":"28","author":"Pierre J.M.","year":"2005","unstructured":"Pierre JM. Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management. Drug Saf 2005; 28 (3) : 191-208.","journal-title":"Drug Saf."},{"key":"ref2","first-page":"36","volume":"2","author":"Mathews M.","year":"2005","unstructured":"Mathews M, Gratz S, Adetunji B, George V, Mathews M, Basil B. Antipsychotic-induced movement disorders: Evaluation and treatment. Psychiatry (Edgmont Pa) 2005; 2 (3) : 36-41.","journal-title":"Psychiatry (Edgmont Pa.)"},{"key":"ref3","first-page":"617","volume":"81","author":"Muench J.","year":"2010","unstructured":"Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician 2010; 81 (5) : 617-22.","journal-title":"Am. Fam. Physician"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1517\/14656566.2012.656590","volume":"13","author":"Cha D.S.","year":"2012","unstructured":"Cha DS, McIntyre RS. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother 2012; 13 (11) : 1587-98.","journal-title":"Expert Opin. Pharmacother."},{"key":"ref5","first-page":"1158","volume":"38","author":"Frances A.","year":"1987","unstructured":"Frances A, Weiden P. Promoting compliance with outpatient drug treatment. Hosp Community Psychiatry 1987; 38 (11) : 1158-60.","journal-title":"Hosp. Community Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/archinte.1989.00390110070015","volume":"149","author":"Miller L.G.","year":"1989","unstructured":"Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989; 149 (11) : 2486-92.","journal-title":"Arch. Intern. Med."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1176\/ajp.135.7.851","volume":"135","author":"Kane J.","year":"1978","unstructured":"Kane J, Rifkin A, Quitkin F, Klein DF. Extrapyramidal side effects with lithium treatment. Am J Psychiatry 1978; 135 (7) : 851-3.","journal-title":"Am. J. Psychiatry"},{"key":"ref8","first-page":"148","volume":"22","author":"Madhusoodanan S","year":"2010","unstructured":"Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyramidal symptoms associated with antidepressants: A review of the literature and an analysis of spontaneous reports. Ann Clin psychiatry Off J Am Acad Clin Psychiatr 2010; 22 (3) : 148-56.","journal-title":"Ann Clin psychiatry Off J Am Acad Clin Psychiatr."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00228-017-2247-x","volume":"73","author":"Jhang K-M.","year":"2017","unstructured":"Jhang K-M, Huang J-Y, Nfor ON, et al. Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine. Eur J Clin Pharmacol 2017; 73 (7) : 911-6.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fneur.2015.00075","volume":"6","author":"Asser A.","year":"2015","unstructured":"Asser A, Taba P. Psychostimulants and movement disorders. Front Neurol 2015; 6 : 75.","journal-title":"Front. Neurol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.18549\/PharmPract.2020.4.2111","volume":"18","author":"Ibrahim O.M.","year":"2020","unstructured":"Ibrahim OM, Ibrahim RM, Meslamani AZA, Mazrouei NA. Dispensing errors in community pharmacies in the United Arab Emirates: investigating incidence, types, severity, and causes. Pharm Pract (Granada) 2020; 18 (4) : 2111. https:\/\/doi.org\/\/10.1002\/14651858.CD000336.pub2 [Granada].","journal-title":"Pharm. Pract. (Granada)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-020-01126-w","author":"Abdel-Qader D.H.","year":"2020","unstructured":"Abdel-Qader DH, Al Meslamani AZ, Lewis PJ, Hamadi S. Incidence, nature, severity, and causes of dispensing errors in community pharmacies in Jordan. Int J Clin Pharm 2020.","journal-title":"Int. J. Clin. Pharm."},{"key":"ref13","author":"Mohamed Ibrahim O","year":"2020","unstructured":"Mohamed Ibrahim O, Ibrahim RM, Abdel-Qader DH, Al Meslamani AZ, Al Mazrouei N. Evaluation of Telepharmacy Services in Light of COVID-19. Telemed e-Health [Internet] 2020.","journal-title":"Telemed e-Health [Internet]."},{"key":"ref14","author":"Ibrahim OM","year":"2020","unstructured":"Ibrahim OM, Ibrahim RM, Meslamani AZ, Al , Mazrouei N, Al . Role of telepharmacy in pharmacist counselling to coronavirus disease 2019 patients and medication dispensing errors. J Telemed Telecare 2020. 1357633X20964347.","journal-title":"J Telemed Telecare."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10900-020-00896-8","author":"Abdel-Qader D.H.","year":"2020","unstructured":"Abdel-Qader DH, Al Meslamani AZ. Knowledge and Beliefs of Jordanian Community Toward E-cigarettes: A National Survey. J Community Health 2020.","journal-title":"J. Community Health"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0018578720942231","volume":"0","author":"Abdel-Qader D.H.","unstructured":"Abdel-Qader DH, Ismael NS, Al Meslamani AZ, Albassam A, El-Shara\u2019 AA, Lewis PJ, et al. The Role of Clinical Pharmacy in Preventing Prescribing Errors in the Emergency Department of a Governmental Hospital in Jordan: A Pre-Post Study. Hosp Pharm 0 (0) 0018578720942231 [Internet].","journal-title":"Hosp. Pharm."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40267-020-00797-9","author":"Abdel-Qader D.H.","year":"2020","unstructured":"Abdel-Qader DH, Albassam A, Ismael NS, El-Shara\u2019 AA, Al Meslamani AZ, Lewis PJ, et al. Community pharmacists\u2019 knowledge of and attitudes toward antibiotic use, resistance, and self-medication in Jordan. Drugs Ther Perspect 2020. [Internet].","journal-title":"Drugs Ther. Perspect."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.56499\/jppres20.902_8.6.525","volume":"8","author":"Abdel-qader D.H.","year":"2020","unstructured":"Abdel-qader DH, Albassam A, Ismael NS, Aljamal MS, Chen L, Hamadi S, et al. Herbal medicine use in the Jordanian population\u202f: A nationally representative cross-sectional survey Study design. J Pharm Pharmacogn Res [Internet] 2020; 8 (6) : 525-36. http:\/\/jppres.com\/jppres\/herbal-medicine-use-in-the-jordanian-population\/","journal-title":"J Pharm Pharmacogn Res [Internet]"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.sapharm.2016.05.050","volume":"13","author":"Alefan Q.","year":"2017","unstructured":"Alefan Q, Karasneh A, El-Dahiyat F, Alshara M, Abu-Naser D. Translation and validation of the Arabic version of generic medicines scale. Res Social Adm Pharm 2017; 13 (3) : 553-63.","journal-title":"Res. Social Adm. Pharm."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1192\/S1749367600006834","volume":"1","author":"Takriti A.","year":"2004","unstructured":"Takriti A. Psychiatry in Jordan. Int Psychiatry 2004; 1 (5) : 9-11.","journal-title":"Int. Psychiatry"},{"key":"ref21","first-page":"115","volume":"41","author":"Allsbrook M.","year":"2016","unstructured":"Allsbrook M, Fries BE, Szafara KL, Regal RE. Do SSRI Antidepressants Increase The Risk of Extrapyramidal Side Effects In Patients Taking Antipsychotics? P&T 2016; 41 (2) : 115-9.","journal-title":"P&T"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/mds.20989","volume":"21","author":"Mueller A.","year":"2006","unstructured":"Mueller A, Reuner U, Landis B, Kitzler H, Reichmann H, Hummel T. Extrapyramidal symptoms in Wilson\u2019s disease are associated with olfactory dysfunction. Mov Disord 2006; 21 (9) : 1311-6. https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/mds.20989 [Internet].","journal-title":"Mov. Disord."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/JCP.0b013e3181f14098","volume":"30","author":"Novick D.","year":"2010","unstructured":"Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol 2010; 30 (5) : 531-40.","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/0974-5009.175458","volume":"43","author":"Hiremath S.","year":"2016","unstructured":"Hiremath S, Desai M. Amitriptyline induced cervical dystonia. J Sci Soc 2016; 43 : 38.","journal-title":"J Sci Soc."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.47102\/annals-acadmed.sg.202023","volume":"49","author":"Rissardo J.P.","year":"2020","unstructured":"Rissardo JP, Caprara ALF. The Link Between Amitriptyline and Movement Disorders: Clinical Profile and Outcome. Ann Acad Med Singapore 2020; 49 (4) : 236-51.","journal-title":"Ann. Acad. Med. Singapore"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5958\/2394-2061.2016.00033.1","volume":"8","author":"Gedam S.","year":"2017","unstructured":"Gedam S, Goyal A, Shivji I. Acute dystonia with concomitant use of amitriptyline and paroxetine. Open J Psychiatry Allied Sci 2017; 8 : 84.","journal-title":"Open J Psychiatry Allied Sci."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3949\/ccjm.73.4.351","volume":"73","author":"Khawam E.A.","year":"2006","unstructured":"Khawam EA, Laurencic G, Malone DA Jr. Side effects of antidepressants: an overview. Cleve Clin J Med 2006; 73 (4) : 351-353, 356-361.","journal-title":"Cleve. Clin. J. Med."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00023210-200418020-00003","volume":"18","author":"Jim\u00e9nez-Jim\u00e9nez F.J.","year":"2004","unstructured":"Jim\u00e9nez-Jim\u00e9nez FJ, Puertas I, de Toledo-Heras M. Drug-induced myoclonus: frequency, mechanisms and management. CNS Drugs 2004; 18 (2) : 93-104. [Internet].","journal-title":"CNS Drugs"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1600-0447.1992.tb01465.x","volume":"85","author":"Lejoyeux M.","year":"1992","unstructured":"Lejoyeux M, Rouillon F, Ad\u00e8s J, Gorwood P. Neural symptoms induced by tricyclic antidepressants: phenomenology and pathophysiology. Acta Psychiatr Scand 1992; 85 (4) : 249-56.","journal-title":"Acta Psychiatr. Scand."},{"key":"ref30","first-page":"2018","volume":"2018","author":"Correia P.","year":"2018","unstructured":"Correia P, Ribeiro JA, Bento C, Sales F. Negative myoclonus secondary to paroxetine intake. BMJ Case Rep 2018; 2018 (Apr) : 2018.","journal-title":"BMJ Case Rep."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s00415-016-8357-z","volume":"264","author":"Janssen S.","year":"2017","unstructured":"Janssen S, Bloem BR, van de Warrenburg BP. The clinical heterogeneity of drug-induced myoclonus: an illustrated review. J Neurol 2017; 264 (8) : 1559-66.","journal-title":"J. Neurol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/10401239409148839","volume":"6","author":"Black K.J.","year":"1994","unstructured":"Black KJ, Kilzieh N. Severe imipramine-induced myoclonus in a patient with psychotic bipolar depression, catatonia, and schizencephaly. Ann Clin Psychiatry 1994; 6 (1) : 45-9. [Internet].","journal-title":"Ann. Clin. Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e100026.","DOI":"10.1136\/gpsych-2018-100026","volume":"32","author":"Weng J","year":"2019","unstructured":"Weng J, Zhang Y, Li H, Shen Y, Yu W. Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia. Gen psychiatry 2019; 32 (1) : e100026..","journal-title":"Gen psychiatry."},{"key":"ref34","first-page":"20","author":"Kirgaval R.","year":"2017","unstructured":"Kirgaval R, Revanakar S, Srirangapattna C. Prevalence of Extrapyramidal Side Effects in Patients on Antipsychotics Drugs at a Tertiary Care Center5. J Psychiatry 2017; 20.","journal-title":"J. Psychiatry"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071343","volume":"8","author":"Jiang J.","year":"2013","unstructured":"Jiang J, See YM, Subramaniam M, Lee J. Investigation of cigarette smoking among male schizophrenia patients. PLoS One 2013; 8 (8) e71343","journal-title":"PLoS One"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.pnpbp.2019.02.011","volume":"92","author":"Huang H.","year":"2019","unstructured":"Huang H, Dong M, Zhang L, et al. Psychopathology and extrapyramidal side effects in smoking and non-smoking patients with schizophrenia: Systematic review and meta-analysis of comparative studies. Prog Neuropsychopharmacol Biol Psychiatry 2019; 92 : 476-82. http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0278584618307875 [Internet].","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.jcp.0000203200.96205.34","volume":"26","author":"Hedenmalm K.","year":"2006","unstructured":"Hedenmalm K, G\u00fczey C, Dahl M-L, Yue Q-Y, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006; 26 (2) : 192-7.","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref38","first-page":"185","volume":"28","author":"Chong S-A.","year":"2003","unstructured":"Chong S-A, Tan E-C, Tan CH, Mythily . Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci 2003; 28 (3) : 185-9. https:\/\/europepmc.org\/articles\/PMC161742 [Internet].","journal-title":"J. Psychiatry Neurosci."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0006-3223(91)90163-G","volume":"30","author":"Menza M.A.","year":"1991","unstructured":"Menza MA, Grossman N, Van Horn M, Cody R, Forman N. Smoking and movement disorders in psychiatric patients. Biol Psychiatry 1991; 30 (2) : 109-15. http:\/\/www.sciencedirect.com\/science\/article\/pii\/000632239190163G [Internet].","journal-title":"Biol. Psychiatry"}],"container-title":["Clinical Practice &amp; Epidemiology in Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/clinical-practice-and-epidemiology-in-mental-health.com\/contents\/volumes\/V17\/CPEMH-17-1\/CPEMH-17-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/clinical-practice-and-epidemiology-in-mental-health.com\/contents\/volumes\/V17\/CPEMH-17-1\/CPEMH-17-1.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/clinical-practice-and-epidemiology-in-mental-health.com\/contents\/volumes\/V17\/CPEMH-17-1\/CPEMH-17-1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:04:22Z","timestamp":1724472262000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinical-practice-and-epidemiology-in-mental-health.com\/VOLUME\/17\/PAGE\/1\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2,16]]}},"alternative-id":["CPEMH-17-1"],"URL":"https:\/\/doi.org\/10.2174\/1745017902117010001","relation":{},"ISSN":["1745-0179"],"issn-type":[{"value":"1745-0179","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-7-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-8","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}